This Pegasys market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth observed in the historic period can be attributed to several factors, including the increasing prevalence of chronic hepatitis C and B, the rising burden of liver diseases, the adoption of combination therapies, the expansion of healthcare infrastructure, improved access to hepatitis testing, favorable regulatory approvals, inclusion in treatment guidelines, and a growing awareness of the importance of early diagnosis and treatment.
The growth anticipated in the forecast period can be attributed to factors such as the increasing adoption of direct-acting antivirals alongside Pegasys, a growing focus on personalized treatment approaches, rising government initiatives for hepatitis elimination, increased research into new hepatitis treatments, a heightened interest in improving patient adherence to antiviral regimens, and continued regulatory support for Pegasys. Key trends during this period include advancements in biosimilar development, innovative digital health solutions, progress in pharmaceutical manufacturing, and strategic collaborations and partnerships aimed at expanding access to treatment and improving patient outcomes.
The growing prevalence of hepatitis B is expected to significantly drive the growth of the Pegasys market. Hepatitis B is a viral infection that primarily affects the liver, potentially leading to chronic conditions, cirrhosis, and liver cancer. The increase in hepatitis B cases is attributed to factors such as unprotected sexual contact, intravenous drug use, and insufficient vaccination coverage in some areas. Pegasys works by enhancing the immune system to control the replication of the virus and reduce liver damage. For example, in April 2024, the European Centre for Disease Prevention and Control reported 28,855 cases of hepatitis B virus infection across 30 EU/EEA Member States in 2022, marking a 78% increase from 16,187 cases in the previous year. The 2022 total represents a rate of 8.5 cases per 100,000 people. As the global prevalence of hepatitis B rises, the demand for Pegasys is expected to increase.
A significant trend in the Pegasys market is its expanding use in treating other conditions beyond its original indications, such as polycythemia vera (PV) and essential thrombocythemia (ET). Pegasys helps regulate abnormal blood cell production, making it valuable in treating myeloproliferative neoplasms. For instance, in July 2024, pharmaand GmbH, an Austria-based pharmaceutical company, received approval from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Pegasys (peginterferon alfa-2a) as a treatment for all eligible patients with polycythemia vera or essential thrombocythemia. While Pegasys is already approved for treating chronic hepatitis B and C in both adults and children, its use has expanded with the inclusion of the drug in oncology guidelines for myeloproliferative neoplasms, PV, and ET.
In July 2022, DKSH Healthcare, a market expansion service provider based in Switzerland, entered into a partnership with pharmaand GmbH to distribute Pegasys in Hong Kong and Macau. DKSH is responsible for the distribution, marketing, sales, and regulatory services of Pegasys in these regions, focusing on expanding its market presence. Pegasys is used to treat chronic hepatitis B and C, either alone or in combination with other medications, and the collaboration is aimed at enhancing the product’s reach in these territories.
Major companies operating in the pegasys market are Roche Holding AG and pharmaand GmbH.
North America was the largest region in the pegasys market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pegasys report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pegasys market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Pegasys is a brand of pegylated interferon alfa-2a used to treat chronic hepatitis B and C, as well as certain cancers, including chronic myelogenous leukemia and malignant melanoma. It enhances the body's immune response to combat viral infections and cancer cells. Administered via subcutaneous injection, the pegylation process extends its half-life, allowing for less frequent dosing compared to non-pegylated interferons.
Pegasys is primarily indicated for chronic hepatitis C and chronic hepatitis B. Chronic hepatitis C is a long-term liver infection caused by the hepatitis C virus (HCV), which can result in severe liver damage, cirrhosis, or liver cancer if untreated. Pegasys is used as part of a treatment regimen to boost the immune response and combat the virus. It is distributed through hospital pharmacies, retail pharmacies, and online platforms, serving end users such as hospitals, clinics, ambulatory care settings, and home care providers.
The pegasys market research report is one of a series of new reports that provides pegasys market statistics, including pegasys industry global market size, regional shares, competitors with a pegasys market share, detailed pegasys market segments, market trends and opportunities, and any further data you may need to thrive in the pegasys industry. This pegasys market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pegasys market consists of sales of monovalent and combination formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth observed in the historic period can be attributed to several factors, including the increasing prevalence of chronic hepatitis C and B, the rising burden of liver diseases, the adoption of combination therapies, the expansion of healthcare infrastructure, improved access to hepatitis testing, favorable regulatory approvals, inclusion in treatment guidelines, and a growing awareness of the importance of early diagnosis and treatment.
The growth anticipated in the forecast period can be attributed to factors such as the increasing adoption of direct-acting antivirals alongside Pegasys, a growing focus on personalized treatment approaches, rising government initiatives for hepatitis elimination, increased research into new hepatitis treatments, a heightened interest in improving patient adherence to antiviral regimens, and continued regulatory support for Pegasys. Key trends during this period include advancements in biosimilar development, innovative digital health solutions, progress in pharmaceutical manufacturing, and strategic collaborations and partnerships aimed at expanding access to treatment and improving patient outcomes.
The growing prevalence of hepatitis B is expected to significantly drive the growth of the Pegasys market. Hepatitis B is a viral infection that primarily affects the liver, potentially leading to chronic conditions, cirrhosis, and liver cancer. The increase in hepatitis B cases is attributed to factors such as unprotected sexual contact, intravenous drug use, and insufficient vaccination coverage in some areas. Pegasys works by enhancing the immune system to control the replication of the virus and reduce liver damage. For example, in April 2024, the European Centre for Disease Prevention and Control reported 28,855 cases of hepatitis B virus infection across 30 EU/EEA Member States in 2022, marking a 78% increase from 16,187 cases in the previous year. The 2022 total represents a rate of 8.5 cases per 100,000 people. As the global prevalence of hepatitis B rises, the demand for Pegasys is expected to increase.
A significant trend in the Pegasys market is its expanding use in treating other conditions beyond its original indications, such as polycythemia vera (PV) and essential thrombocythemia (ET). Pegasys helps regulate abnormal blood cell production, making it valuable in treating myeloproliferative neoplasms. For instance, in July 2024, pharmaand GmbH, an Austria-based pharmaceutical company, received approval from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Pegasys (peginterferon alfa-2a) as a treatment for all eligible patients with polycythemia vera or essential thrombocythemia. While Pegasys is already approved for treating chronic hepatitis B and C in both adults and children, its use has expanded with the inclusion of the drug in oncology guidelines for myeloproliferative neoplasms, PV, and ET.
In July 2022, DKSH Healthcare, a market expansion service provider based in Switzerland, entered into a partnership with pharmaand GmbH to distribute Pegasys in Hong Kong and Macau. DKSH is responsible for the distribution, marketing, sales, and regulatory services of Pegasys in these regions, focusing on expanding its market presence. Pegasys is used to treat chronic hepatitis B and C, either alone or in combination with other medications, and the collaboration is aimed at enhancing the product’s reach in these territories.
Major companies operating in the pegasys market are Roche Holding AG and pharmaand GmbH.
North America was the largest region in the pegasys market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pegasys report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pegasys market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Pegasys is a brand of pegylated interferon alfa-2a used to treat chronic hepatitis B and C, as well as certain cancers, including chronic myelogenous leukemia and malignant melanoma. It enhances the body's immune response to combat viral infections and cancer cells. Administered via subcutaneous injection, the pegylation process extends its half-life, allowing for less frequent dosing compared to non-pegylated interferons.
Pegasys is primarily indicated for chronic hepatitis C and chronic hepatitis B. Chronic hepatitis C is a long-term liver infection caused by the hepatitis C virus (HCV), which can result in severe liver damage, cirrhosis, or liver cancer if untreated. Pegasys is used as part of a treatment regimen to boost the immune response and combat the virus. It is distributed through hospital pharmacies, retail pharmacies, and online platforms, serving end users such as hospitals, clinics, ambulatory care settings, and home care providers.
The pegasys market research report is one of a series of new reports that provides pegasys market statistics, including pegasys industry global market size, regional shares, competitors with a pegasys market share, detailed pegasys market segments, market trends and opportunities, and any further data you may need to thrive in the pegasys industry. This pegasys market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pegasys market consists of sales of monovalent and combination formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Pegasys Market Characteristics4. Pegasys Market Trends and Strategies5. Pegasys Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Pegasys Pricing Analysis & Forecasts30. Global Pegasys Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Pegasys Market32. Recent Developments in the Pegasys Market
3. Pegasys Market Biologic Drug Characteristics
6. Global Pegasys Growth Analysis and Strategic Analysis Framework
8. Pegasys Market Segmentation
9. Global Pegasys Epidemiology of Clinical Indications
10. Pegasys Market Regional and Country Analysis
11. Asia-Pacific Pegasys Market
12. China Pegasys Market
13. India Pegasys Market
14. Japan Pegasys Market
15. Australia Pegasys Market
16. South Korea Pegasys Market
17. Western Europe Pegasys Market
18. UK Pegasys Market
19. Germany Pegasys Market
20. France Pegasys Market
21. Eastern Europe Pegasys Market
22. North America Pegasys Market
23. USA Pegasys Market
24. Canada Pegasys Market
25. South America Pegasys Market
26. Middle East Pegasys Market
27. Africa Pegasys Market
28. Pegasys Market Competitive Landscape and Company Profiles
29. Global Pegasys Market Pipeline Analysis
33. Pegasys Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Pegasys Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on pegasys market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for pegasys? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pegasys market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Chronic Hepatitis C; Chronic Hepatitis B2) by Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
3) by End-Users: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Mentioned: Roche Holding AG; pharmaand GmbH
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Roche Holding AG
- pharmaand GmbH
